18F-FDG uptake on PET could be a predictive marker of Excision Repair Cross-Complementation Group 1 (ERCC1) expression in patients with thoracic neoplasms?

Neoplasma

Volumn 59, Issue 3, 2012, Pages 257-263

  Kaira, K ^a   Endo, M ^a   Shukuya, T ^a   Kenmotsu, H ^a   Naito, T ^a   Ono, A ^a   Tsuya, A ^a   Nakamura, Y ^a   Takahashi, T ^a   Murakami, H ^a   Kondo, H ^a   Nakajima, T ^a   Yamamoto, N ^a  

^a SHIZUOKA CANCER CENTER   (Japan)

Author keywords

Biomarker; ERCC1; Predictive; Thoracic neoplasms

Indexed keywords

CD34 ANTIGEN; EXCISION REPAIR CROSS COMPLEMENTING PROTEIN 1; FLUORODEOXYGLUCOSE F 18; GLUCOSE TRANSPORTER 1; TUMOR MARKER; VASCULOTROPIN; DIAGNOSTIC AGENT; DNA BINDING PROTEIN; ENDONUCLEASE; ERCC1 PROTEIN, HUMAN; RADIOPHARMACEUTICAL AGENT; SLC2A1 PROTEIN, HUMAN; VASCULOTROPIN A; VEGFA PROTEIN, HUMAN;

ADENOCARCINOMA; ADULT; AGED; ARTICLE; CANCER STAGING; CAPILLARY DENSITY; FEMALE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LARGE CORE NEEDLE BIOPSY; LUNG METASTASIS; LUNG NON SMALL CELL CANCER; LUNG TUMOR; MAJOR CLINICAL STUDY; MALE; NEUROENDOCRINE TUMOR; PET SCANNER; PLEURA MESOTHELIOMA; POSITRON EMISSION TOMOGRAPHY; PROTEIN EXPRESSION; PULMONARY NEUROENDOCRINE TUMOR; SARCOMA; SQUAMOUS CELL CARCINOMA; THORAX TUMOR; THYMOMA; ENZYME IMMUNOASSAY; METABOLISM; PATHOLOGY; SCINTISCANNING;

AGED; ANTIGENS, CD34; DNA-BINDING PROTEINS; ENDONUCLEASES; FEMALE; FLUORODEOXYGLUCOSE F18; GLUCOSE TRANSPORTER TYPE 1; HUMANS; IMMUNOENZYME TECHNIQUES; MALE; POSITRON-EMISSION TOMOGRAPHY; RADIOPHARMACEUTICALS; THORACIC NEOPLASMS; THYMUS NEOPLASMS; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 84863844937     PISSN: 00282685     EISSN: 13384317     Source Type: Journal    
DOI: 10.4149/neo_2012_033     Document Type: Article

References (19)

1. VOLKER M, MONE MJ, KAMAKAR P, VAN HOFFEN A, SCHUL W. et al. Sequential assembly of the nucleotide excision repair factors in vivo. Mol Cell 2011; 8: 213-24. http://dx.doi.org/10.1016/S1097-2765(01)00281-7
2. SIMON GR, SHARMA S, CANTOR A, SMITH P, BEPLER G. ERCC1 expression is a predictor of survival in resected patients with non-small cell lung cancer. Chest 2005; 127: 978-83. http://dx.doi.org/10.1378/chest.127.3.978
3. OLAUSSEN KA, DUNANT A, FOURET P, BRAMBILLA E, ANDRE F. et al. DNA repair by ERCC1 in non-small-cell lung cancer and cisplatin-based adjuvant chemotherapy. N Engl J Med 2006; 355: 983-91. http://dx.doi.org/10.1056/NEJMoa060570
4. ZHENG Z, CHEN T, LI X, HAURA E, SHARMA A, BEPLER G. DNA synthesis and repair genes RRM1 and ERCC1 in lung cancer. N Engl J Med 2007; 356: 800-8. http://dx.doi.org/10.1056/NEJMoa065411
5. KAIRA K, YAMAMOTO N. Prognostic and predictive factors in resected non-small cell lung cancer. Expert Opin Med Diagn 2010; 4: 1-9. http://dx.doi.org/10.1517/17530059.2010.506214
6. KAIRA K, SERIZAWA M, KOH Y, MIURA S, KAIRA R. et al. Expression of Excision Repair Cross-Complementation Group 1, Breast Cancer Susceptibility 1, and β III-Tubulin in Thymic Epithelial Tumors. J Thorac Oncol. 20116: 606-13.
7. SASAKI R, KOMAKI R, MACAPINLAC H, ERASMUS J, ALLEN P. et al. [18F] fluorodexyglucose uptake by positron emission tomography predicts outcome of non-small-cell lung cancer. J Clin Oncol 2005; 23: 1136-43. http://dx.doi.org/10.1200/JCO.2005.06.129
8. HIGASHI K, UEDA Y, ARISAKA Y, SAKUMA T, NAMBU Y. et al. F-FDG uptake as a biologic prognostic factor for recurrence in patients with surgically resected non-small cell lung cancer. J Nucl Med 2002; 43: 39-45.
9. BENARD F, STERMAN D, SMITH RJ, KAISER LR, ALBELDA SM. et al. Prognostic value of FDG PET imaging in malignant pleural mesothelioma. J Nucl Med 1999; 40: 1241-5.
10. SONG YS, LEE WW, CHUNG JH, PARK SY, KIM YK. et al. Correlation between FDG uptake and glucose transporter type 1 expression in neuroendocrine tumors of the lung. Lung Cancer 2008; 61: 54-60. http://dx.doi.org/10.1016/j.lungcan.2007.11.012
11. KAIRA K, OKUMURA T, OHDE Y, TAKAHASHI T, MURAKAMI H. et al. Correlation between 18F-FDG uptake on PET and molecular biology in metastatic pulmonary tumors. J Nucl Med 2011; 52: 705-11. http://dx.doi.org/10.2967/jnumed.111.087676
12. KAIRA K, ENDO M, ABE M, NAKAGAWA K, OHDE Y. et al. Biologic correlation of 2-[18F]-fluoro-2-deoxy-D-glucose uptake on positron emission tomography in thymic epithelial tumors. J Clin Oncol 2010; 28: 3746-53. http://dx.doi.org/10.1200/JCO.2009.27.4662
13. RUSCH VW. The International Mesothelioma Interest Group. A proposed new international TNM staging system for malignant pleural mesothelioma. Chest 1995; 108; 1122-28. http://dx.doi.org/10.1378/chest.108.4.1122
14. TRAVIS WD, RUSH W, FLIEDER DB. International Histological Classification of Tumors, Histological Typing of Lung and Pleural Tumors, 1999.
15. ROSAI J, SOBIN LH. Histological typing of tumours of the thymus, International histological classification of tumours. 2nd ed. New York: Springer pp1-59, 1999. http://dx.doi.org/10.1007/978-3-642-60157-6_1
16. KAIRA K, MURAKAMI H, MIURA S, KAIRA R, AKAMATSU H. et al. 18F-FDG uptake on help predict outcome and response after treatment in unresectable thymic epithelial tumors. Ann Nucl Med 2011;25:247-53. http://dx.doi.org/10.1007/s12149-010-0455-x
17. ZUCALI PA, GIOVANNETTI E, DESTRO A, MENCOBONI M, CERESOLI GL. et al. Thymidylate synthase and excision repair cross-complementing group-1 as predictors of responsiveness in mesothelioma patients treated with pemetrexed/carboplatin. Clin Cancer Res 2011; 17: 2581-90. http://dx.doi.org/10.1158/1078-0432.CCR-10-2873
18. JUN HJ, AHN MJ, KIM HS, YI SY, HAN J. et al. ERCC1 expression as a predictive marker of squamous cell carcinoma of the head and neck treated with cisplatin-based concurrent chemoradiation. Br J Cancer 2008; 99: 167-72. http://dx.doi.org/10.1038/sj.bjc.6604464
19. VILMAR A, SANTONI-RUIGU E, SORENSEN JB. ERCC1, toxicity and quality of life in advanced NSCLC patients randomized in a large multicentre phase III trial. Eur J Cancer 2010; 46: 1554-62. http://dx.doi.org/10.1016/j.ejca.2010.02.045